The full data from both of those studies will be presented at ASCO, as will another study showing that the company's Herceptin prevents breast cancer tumors with certain genetic defects from returning after surgery.
However, the researchers do not suggest abandoning preventive surgery as an option for women whose genetic history strongly suggests they may be at risk from ovarian cancer.